Last reviewed · How we verify
NCT06089954: ROR
Penn Medicine Biobank Return of Results Program
NA trial testing private web-portal eHealth disclosure of genetic results in Genetic Disease in 2,500 participants. Enrolling by invitation.
1 April 2026
Quick facts
| Lead sponsor | Abramson Cancer Center at Penn Medicine |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 2,500 |
| Start date | 20 October 2023 |
| Primary completion | 1 April 2026 |
| Estimated completion | 31 August 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- private web-portal eHealth disclosure of genetic results
- eHealth education intervention (web or chatbot)
Conditions studied
- Genetic Disease — all drugs for Genetic Disease →
- Cancer — all drugs for Cancer →
- Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
Sponsor
Abramson Cancer Center at Penn Medicine — full company profile →
Who can join
18 and older, any sex, with Genetic Disease or Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this hybrid type 1 effectiveness-implementation study is to evaluate and compare different ways of delivering genetic research results to participants. The main questions the study aims to answer are: * Is sharing actionable genetic research results with participants through a multimedia patient-informed eHealth intervention (e.g. patient portal) no worse than sharing results by telephone or videoconference with a genetic counselor? * Will research participants access an eHealth educational intervention or chatbot education to learn about research results being offered and the option to decline learning their individual research results and how frequently participants choose to decline actionable research results? * Who benefits less and more from digital intervention with return of actionable research results and what barriers exist to using these tools for return of research results outside this study? Participants in the biobank will be offered digital tools to learn about research results being offered and the option to decline receiving these results. Those who don't decline and have an actionable result will be randomly assigned to receive their results with a genetic counselor or through an eHealth portal. Participants will complete surveys before and after receipt of results to understand patient experiences with these methods of education and return of results to determine if digital tools can be used to help ensure more patients get access to research results which could impact their health.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06089954
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Genetic Disease
Currently open trials in the same condition.
- NCT06744543 — Clinical Decision Support to Identify Pediatric Patients With Undiagnosed Genetic Disease · NA · active not recruiting
- NCT06435468 — Biocollection of Rare Pediatric-onset of Autoimmune and Autoinflammatory Diseases · NA · recruiting
- NCT06821386 — N-Care Project: Enhancing Asian-Pacific Collaboration · recruiting
- NCT07365254 — Accurate Assessment and Intervention Research on Newborn Whole Genome Sequencing and Genetic Disease Risk · recruiting
- NCT06725901 — Pediatric Neurogenetic Diagnosis Support Platform · NA · recruiting
Other Abramson Cancer Center at Penn Medicine trials
Trials by the same sponsor.
- NCT07478848 — Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas · Phase 1 · not yet recruiting
- NCT07059611 — Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
- NCT07454499 — Engaging M-health for Symptom Monitoring and Health Promotion for Women on Endocrine Therapy for Breast Cancer (EmSHAPE) · NA · not yet recruiting
- NCT07222241 — Comparing Numbing Techniques in Mohs Micrographic Surgery · NA · recruiting
- NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06089954 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Abramson Cancer Center at Penn Medicine
- Last refreshed: 24 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06089954.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing